Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study
- PMID: 20385893
- PMCID: PMC2872799
- DOI: 10.1212/WNL.0b013e3181d8c20a
Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study
Abstract
Background: In Huntington disease (HD), substantial striatal atrophy precedes clinical motor symptoms. Accordingly, neuroprotection should prevent major cell loss before such symptoms arise. To evaluate neuroprotection, biomarkers such as MRI measures are needed. This requires first establishing the best imaging approach.
Methods: Using a cross-sectional design, we acquired T1-weighted and diffusion-weighted scans in 39 preclinical (pre-HD) individuals and 25 age-matched controls. T1-weighted scans were analyzed with gross whole-brain segmentation and voxel-based morphometry. Analysis of diffusion-weighted scans used skeleton-based tractography. For all imaging measures, we compared pre-HD and control groups and within the pre-HD group we examined correlations with estimated years to clinical onset.
Results: Pre-HD individuals had lower gross gray matter (GM) and white matter (WM) volume. Voxel-wise analysis demonstrated local GM volume loss, most notably in regions consistent with basal ganglia-thalamocortical pathways. By contrast, pre-HD individuals showed widespread reductions in WM integrity, probably due to a loss of axonal barriers. Both GM and WM imaging measures correlated with estimated years to onset.
Conclusions: Using automated, observer-independent methods, we found that GM loss in pre-HD was regionally specific, while WM deterioration was much more general and probably the result of demyelination rather then axonal degeneration. These findings provide important information about the nature, relative staging, and topographic specificity of brain changes in pre-HD and suggest that combining GM and WM imaging may be the best biomarker approach. The empirically derived group difference images from this study are provided as regions-of-interest masks for improved sensitivity in future longitudinal studies.
Figures



Similar articles
-
Longitudinal diffusion changes in prodromal and early HD: Evidence of white-matter tract deterioration.Hum Brain Mapp. 2017 Mar;38(3):1460-1477. doi: 10.1002/hbm.23465. Epub 2017 Jan 3. Hum Brain Mapp. 2017. PMID: 28045213 Free PMC article.
-
Diffusion tensor imaging in presymptomatic and early Huntington's disease: Selective white matter pathology and its relationship to clinical measures.Mov Disord. 2006 Sep;21(9):1317-25. doi: 10.1002/mds.20979. Mov Disord. 2006. PMID: 16755582
-
White-matter lesions drive deep gray-matter atrophy in early multiple sclerosis: support from structural MRI.Mult Scler. 2013 Oct;19(11):1485-92. doi: 10.1177/1352458513478673. Epub 2013 Mar 5. Mult Scler. 2013. PMID: 23462349
-
Seeking brain biomarkers for preventive therapy in Huntington disease.CNS Neurosci Ther. 2011 Oct;17(5):368-86. doi: 10.1111/j.1755-5949.2010.00157.x. Epub 2010 Jun 11. CNS Neurosci Ther. 2011. PMID: 20553306 Free PMC article. Review.
-
Hemispheric dysplasia and hemimegalencephaly: imaging definitions.Childs Nerv Syst. 2014 Nov;30(11):1813-21. doi: 10.1007/s00381-014-2476-6. Epub 2014 Oct 9. Childs Nerv Syst. 2014. PMID: 25296542 Review.
Cited by
-
Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.Drug Des Devel Ther. 2015 Apr 15;9:2179-88. doi: 10.2147/DDDT.S58470. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 25931812 Free PMC article. Review.
-
Linking white matter and deep gray matter alterations in premanifest Huntington disease.Neuroimage Clin. 2016 Feb 26;11:450-460. doi: 10.1016/j.nicl.2016.02.014. eCollection 2016. Neuroimage Clin. 2016. PMID: 27104139 Free PMC article.
-
Altered Intracortical T1-Weighted/T2-Weighted Ratio Signal in Huntington's Disease.Front Neurosci. 2018 Nov 5;12:805. doi: 10.3389/fnins.2018.00805. eCollection 2018. Front Neurosci. 2018. PMID: 30455625 Free PMC article.
-
Basal ganglia-cortical structural connectivity in Huntington's disease.Hum Brain Mapp. 2015 May;36(5):1728-40. doi: 10.1002/hbm.22733. Epub 2015 Jan 30. Hum Brain Mapp. 2015. PMID: 25640796 Free PMC article.
-
Neurofilament light protein in blood predicts regional atrophy in Huntington disease.Neurology. 2018 Feb 20;90(8):e717-e723. doi: 10.1212/WNL.0000000000005005. Epub 2018 Jan 24. Neurology. 2018. PMID: 29367444 Free PMC article.
References
-
- Aylward EH, Sparks BF, Field KM, et al. Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66–72. - PubMed
-
- Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci 2004;5:373–384. - PubMed
-
- Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF. Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008;58:209–225. - PubMed
-
- Aylward EH, Brandt J, Codori AM, et al. Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons. Neurology 1994;44:823–828. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical